Jon Lim, FRCP PhD

👉...cutting-edge science, clinical insights & discussions re: real-world implementation of TIL therapy.

Featuring keynote speakers:
Inge Marie Svane 🇩🇰 & Sebastian Klobuch 🇳🇱.

@sklobuch.bsky.social
@debrajosephs.bsky.social
@turajliclab.bsky.social
@beckilee.bsky.social

Unlocking TIL Therapy: A New Era for Melanoma Care in the UK TIL (Tumour-Infiltrating Lymphocyte) therapy is a transformative, cell-based immunotherapy approach now entering clinical practice for melanoma. This national summit brings together UK and internation...

📣 Final agenda confirmed - only 5 weeks to go!

Join us on 𝟭𝟭 𝗠𝗮𝗿𝗰𝗵 𝟮𝟬𝟮𝟲 in Manchester 🐝 for our inaugural TIL Summit: Unlocking TIL Therapy – A New Era for Melanoma Care in the UK.

Kindly sponsored by The Christie Charity.

Space limited - so don't miss out! For further information & to register:

The beginning of an international partnership between The Christie and the National Cancer Institute of Ukraine The Christie Institute for Cancer Education has welcomed international colleagues from the National Cancer Institute of Ukraine (UNCI) as part of a new education partnership focused on bilateral shari...

One of the projects I’m most proud of since returning to Manchester.

In awe of the resilience of our Ukrainian colleagues delivering cancer care under extraordinary circumstances, and grateful for the generosity of #TeamManchester colleagues in sharing best practice.

🇬🇧 🤝 🇺🇦

Find out more 👇

New Journal for ImmunoTherapy of Cancer review: Steroid-sparing strategies for managing immune-related adverse events jitc.bmj.com/content/14/1...

lab to life

Exciting conference alert!

sites.manchester.ac.uk/from-lab-to-...

Fantastic speakers including Chris Marine, Christian Blank

Melanoma evolution
Local microenvironment of melanoma
Melanoma-host interactions
Precision immunotherapy
Emerging therapeutics
Clinical trials and real-world data

🔗 For further details (deadline 3 June 2026):
www.esmo.org/meeting-cale...

🆕 New on the ESMO events calendar for 2026!

Mark your calendar for the 𝗘𝗦𝗠𝗢 𝗣𝗿𝗲𝗰𝗲𝗽𝘁𝗼𝗿𝘀𝗵𝗶𝗽 𝗼𝗻 𝗧𝘂𝗺𝗼𝘂𝗿-𝗔𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗼𝗳 𝗨𝗻𝗸𝗻𝗼𝘄𝗻 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 (𝗖𝗨𝗣) in Zurich: 18-19 September 2026.

Chaired by the fantastic @oncocook.bsky.social & @benwestphalen.bsky.social.

@myesmo.bsky.social

This is one of the projects I’m most proud of since coming back to (re-)join #TeamManchester faculty. Delighted to welcome and host our Medical Oncology colleagues from UNCI, Kyiv at The Christie.

🇺🇦 🤝 🇬🇧

You’re such an inspiration, Adam! Keep going 🙌.

🚀 Kicking off the new year with our next #ChristieFellowship session!

How do we communicate science well - to patients, the public, and on social media?

Join us for an interactive session on 𝗣𝘂𝗯𝗹𝗶𝗰 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 with Prof @achoud72.bsky.social.

@christieinstitute.bsky.social
@mcrcnews.bsky.social

Thanks to @acir-org.bsky.social for highlighting our article!

Really grateful to you, Evangelos! Your mentorship, guidance and friendship in the lab made a huge difference, especially early on as a new PhD fellow 🤓.

Looking forward to continuing to work closely together in Manchester! 🙌

@uom-dcs.bsky.social
@mcrcnews.bsky.social
@cruk-mi.bsky.social

❗Cross-presentation shapes neoantigen visibility and cancer immunogenicity in #NatureImmunology🤯
www.nature.com/articles/s41...
Huge congratulations @drjonlim.bsky.social 🥂
Inspired and so lucky to have you in #Manchester 🐝
Congratulations to #OliverSchulz, @reisesousalab.bsky.social , @crick.ac.uk

NB 'An important function of the immune system is to eradicate pre-malignant and malignant cells in the early phase of tumor development. For this reason, the use of carcinogens rather than transplantable tumor cell lines in mice can offer a more refined experimental approach (...)'

...and follow this thread 🧵 for how the story evolved:

DC cross-presentation of dead cell F-actin antigens sculpts tumor evolution Lim, Schulz, et al. studied the functioning of the F-actin receptor DNGR-1 on cDC1s, and the impact of cross-presentation on immunoediting of tumors using chemical carcinogenesis models. Dead cell-ass...

How does the immune system decide which tumour antigens remain visible over time❓

Our study on dendritic cell cross-presentation of dead-cell, F-actin–associated antigens, and its impact on tumour immunogenicity and cancer evolution, was featured in @acir-org.bsky.social.

Read further here 👇

🤔 Do patients with cancer and clinicians see disease status the same way?

Our study highlights where understanding aligns - and where it doesn’t - underscoring the importance of clear communication in palliative care.

Presented first at #ESMOGI24, now published in full:
doi.org/10.1007/s003...

🚨 NEW opportunity! 🚨

We’re recruiting a Translational Research Programme Manager to support delivery of the recently launched MRC-funded 𝗥𝗜𝗦𝗘 programme at @uom-dcs.bsky.social @manchester.ac.uk - based in the Withington campus.

🗓️ Deadline: 30th January 2026.

🔗 To find out more and to apply:

We cover:
• TCR-T, CAR-T, TIL & NK-cell approaches
• Lessons from early clinical studies
• Key biological & practical challenges
• Where the field may be heading next

Will cell therapy work in sarcoma❓

#Sarcoma #CellTherapy #CancerImmunotherapy #TranslationalResearch

Cell therapy in sarcoma: current landscape and future directions Sarcomas are rare malignancies of mesenchymal origin, characterized by significant biological and clinical heterogeneity. Many subtypes demonstrate limited sensitivity to standard systemic treatments,...

🧬 Cell therapy in sarcoma: what do we know so far?

Our new #OpenAccess review in the 𝘑 𝘐𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳 𝘊𝘢𝘯𝘤𝘦𝘳 @sitcancer.bsky.social summarises the current landscape of cell therapy in sarcoma.

@tkoraysahin.bsky.social @lizconnolly.bsky.social

A big welcome to our #MedicalOncology colleagues from National Cancer Institute of Ukraine 🇺🇦. Looking forward to working with you all this week and beyond!

@mcrcnews.bsky.social
@christieinstitute.bsky.social

How Dying Tumor Cells Alert the Immune System To Fight Cancer New research shows how dendritic cells sound the alarm in response to dead cancer cells.

As featured in Technology Networks 👇

www.technologynetworks.com/tn/news/how-...

Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...

Congrats to the team of @reisesousalab.bsky.social for this beautiful work in @natimmunol.nature.com showing that "Neoantigen cross-presentation by cDC1 can determine the immune visibility of the tumor mutational landscape and sculpt cancer evolution by immunoediting"

www.nature.com/articles/s41...

Lifting cancer's invisibility cloak: Dying tumor cells alert the immune system The immune system provides constant surveillance for the body, aiming to spot and eliminate disease-causing microbes or cancerous cells.

Dendritic cells detect dead tumor cells using the DNGR-1 receptor, helping the immune system recognize and target cancer cells with specific mutations. This insight may inform future immunotherapies. doi.org/hbhtf6

Thanks for highlighting our paper in your wonderful News & Views!

The ‘Big Picture’: Immune Response produced by @wellcometrust.bsky.social.

🔗 www.stem.org.uk/resources/li...

DNGR-1 enables cDC1 to sculpt cancer immunoediting through selective cross-presentation of F-actin-tethered neoantigens
@natimmunol.nature.com @reisesousalab.bsky.social
@crick.ac.uk
www.nature.com/articles/s41...
www.nature.com/articles/s41...
preview by @magarianblander.bsky.social

Elegant proof that a DNGR-1–dependent mechanism isn’t just sensing tumors but editing them in carcinogenesis

A key point is that the effect is qualitative not quantitative—same mutation burden but selective loss of neoantigens = immune pressure

Thanks for sharing @drjonlim.bsky.social & congrats 🥳

Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity - Nature Immunology Here the authors show DNGR-1 expressed by cDC1s promotes CD8⁺ T cell priming to cytoskeletal neoantigens from dying tumor cells, thereby shaping cancer immune visibility and tumor evolution through im...

#WeekendRead! #DendriticCellPower! @reisesousalab.bsky.social @drjonlim.bsky.social &co show @natimmunol.nature.com that cDC1s exploit DNGR1 to crosspresent #tumor #neoantigens derived from F-actin binding proteins protecting against tumorigenesis but favoring cancer immunoediting!

Thank you 🙏.